Quarterly report pursuant to Section 13 or 15(d)

LICENSED TECHNOLOGY (Details Narrative)

v3.20.2
LICENSED TECHNOLOGY (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Apr. 17, 2020
Apr. 02, 2020
Nov. 04, 2018
May 15, 2015
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Nov. 04, 2019
Indefinite-lived Intangible Assets [Line Items]                      
Due to Related Parties, Current         $ 30,127,000     $ 30,127,000   $ 27,400,000  
Allocated Share Based Compensation Expense Restricted Stock   $ 20,000,000                  
Payments for Royalties   $ 8,000,000                  
License to be paid $ 8,000,000                    
Interest Payable     $ 1,000,000                
Debt Instrument, Maturity Date   Nov. 04, 2020                  
License termination date May 02, 2020                    
Debt instrument, periodic payment, principal               28,000,000      
Debt instrument, increase, accrued interest               2,100,000      
Non-cash licensed technology impairment charge         $ 32,900,000 32,916,000    
Amortization of intangible assets         43,000   $ 1,293,000 1,381,000 $ 3,931,000    
Abeona Therapeutics LLC [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
Finite-Lived Intangible Asset, Useful Life       20 years              
Original License Agreement [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
License to be paid                     $ 10,000,000
Eb Agreement [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
License to be paid                     3,000,000
Eb Agreement [Member] | Non cash Or Part Non cash Acquisition Non cash Financial Or Equity Instrument Consideration Value Of Warrants Issued1                      
Indefinite-lived Intangible Assets [Line Items]                      
License to be paid                     $ 8,000,000
REGENXBIO [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
Due remains value               28,000,000      
REGENXBIO [Member] | Licensing Agreements [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
Royalty Expense     180,000,000                
Allocated Share Based Compensation Expense Restricted Stock     20,000,000                
IncomeTax Reconciliation Current Year Reserve     10,000,000                
Due to Related Parties, Current     10,000,000                
Allocated Share Based Compensation Expense Restricted Stock     20,000,000                
Payments for Royalties     $ 60,000,000                
Finite-Lived Intangible Asset, Useful Life     8 years                
Loss Contingency Accrual         $ 8,000,000     8,000,000      
Payments for Legal Settlements               $ 20,000,000      
REGENXBIO [Member] | Licensing Agreements [Member] | Maximum [Member]                      
Indefinite-lived Intangible Assets [Line Items]                      
Debt Instrument, Face Amount     $ 100,000,000